Table 3 Risk factors for TNF inhibitor discontinuation in RA patients

Age at start of biologics

1.00 (0.99 – 1.02)

0.66

1.09 (1.02 – 1.16)

<0.01

1.00 (0.99 – 1.02)

0.64

Sex, female

1.06 (0.65 – 1.74)

0.81

1.81 (0.64 – 5.12)

0.27

0.84 (0.47 – 1.49)

0.55

Switcher vs. first user

0.55 (0.35 – 0.86)

<0.01

0.43 (0.16 – 1.22)

0.11

0.57 (0.34 – 0.94)

0.03

Disease duration, per year

0.97 (0.95 – 0.997)

0.03

0.96 (0.91 – 1.00)

0.05

0.97 (0.94 – 0.997)

0.03

Biologics

 Etanercept

1.00

1.00

1.00

 Infliximab

1.44 (0.92 – 2.27)

0.11

0.43 (0.10 – 1.97)

0.28

1.81 (1.11 – 2.95)

0.02

 Adalimumab

0.88 (0.59 – 1.32)

0.54

0.72 (0.30 – 1.74)

0.46

0.86 (0.54 – 1.37)

0.53

Concomitant use of methotrexate

0.72 (0.51 – 1.01)

0.06

0.44 (0.21 – 0.91)

0.03

0.91 (0.62 – 1.35)

0.64

Concomitant glucocorticoid dosage

 <5 mg/day

1.00

1.00

1.00

 ≥5 mg/day

1.05 (0.76 – 1.46)

0.75

1.18 (0.53 – 2.62)

0.68

0.97 (0.67 – 1.41)

0.89

Comorbidity^a

0.91 (0.64 – 1.29)

0.59

0.37 (0.15 – 0.91)

0.03

1.04 (0.71 – 1.52)

0.83